Igg1 Trispecific Monoclonal Antibody Against T-Cell Receptor Cd3, B-Cell Maturation Antigen And G Protein-Coupled Receptor Class C Group 5 Member D

4 trials 4 recruiting Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

4 Recruiting

0 Completed trials

3 Sponsors

10 Countries

Phase III

Phase II

Phase III: 2 Phase II: 2

Oversight events:

3 temporary halts across 1 trial

View oversight register →

Indications tested

Plasma cell myeloma refractory 3

Sponsors using this IMP

Janssen - Cilag International 3 Emn Trial Office S.r.l. Impresa Sociale 1 European Myeloma Network B.V. 1

All trials

4 total

A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Recruiting

2025-523815-12-00 Phase III 7 countries Janssen Cilag International
A Phase 2 Study of JNJ-79635322 in Participants with RRMM Recruiting

2025-521976-80-00 Phase II 2 countries Janssen Cilag International
A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma Recruiting

2025-522007-18-00 Phase III 7 countries Janssen Cilag International
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS Recruiting

2023-505221-14-00 Phase II 5 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.

Showing 1–4 of 4 trials

← All drugs A–Z